Journal of Cellular Biochemistry is a premier academic journal dedicated to advancing the field of biochemistry and cellular biology. Published by Wiley, this influential journal has a significant impact factor that underscores its relevance and authority within the scientific community. With its ISSN 0730-2312 and E-ISSN 1097-4644, the journal has been on the frontier of research since its inception in 1982, and is expected to continue publishing cutting-edge studies through 2024. As evidenced by its ranking in the 2023 Scopus Quartiles, it holds a rank of Q2 in Biochemistry and Q3 in both Cell and Molecular Biology, placing it among the top tiers of scientific journals in these disciplines. The Journal of Cellular Biochemistry serves as a vital resource for researchers, professionals, and students alike, providing a platform for the dissemination of innovative ideas and findings that shape our understanding of cellular processes and biochemical pathways. Though it does not currently offer Open Access options, its robust peer-review process ensures that each publication meets the highest academic standards, thus solidifying its esteemed position in the landscape of biochemical research.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Computational and Structural Biotechnology Journal is a premier open-access journal published by Elsevier, focusing on the intersection of computer science and molecular biology. Since its inception in 2012, the journal has established itself as a leading platform for innovative research, featuring groundbreaking studies in biochemistry, biophysics, biotechnology, and genetics. With a remarkable Q1 ranking in multiple categories, including Biochemistry and Genetics, it stands out for its high impact, evidenced by its strong Scopus ranking percentile scores. As a vital resource for researchers, professionals, and students, the journal aims to foster the dissemination of essential findings that leverage computational techniques to explore complex biological systems. In a rapidly evolving scientific landscape, Computational and Structural Biotechnology Journal serves as an indispensable resource for those looking to contribute and stay abreast of major advancements in the field.

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

Current Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

MOLECULAR AND CELLULAR PROBES, published by Academic Press Ltd - Elsevier Science Ltd, stands as a prominent journal at the intersection of cell and molecular biology. With an ISSN of 0890-8508 and an E-ISSN of 1096-1194, this journal has consistently contributed to the scientific discourse since its inception in 1987, converging its scholarly content through to 2024. As a member of Q3 in both Cell Biology and Molecular Biology categories, it provides a platform for innovative research and critical insights into cellular mechanisms, signaling pathways, and molecular interactions. Its Scopus rankings position it within the top half of its categories, fostering a vibrant academic community that supports the exploration and advancement of biochemistry, genetics, and molecular biology. Although it does not currently offer Open Access, the high-quality peer-reviewed articles published in MOLECULAR AND CELLULAR PROBES are invaluable resources for researchers, professionals, and students who seek to stay at the forefront of breakthroughs in these essential fields.

CELL BIOCHEMISTRY AND BIOPHYSICS is a distinguished journal published by HUMANA PRESS INC, focusing on critical advancements in the fields of biochemistry, biophysics, and cell biology. Since its establishment, the journal has provided a robust platform for the dissemination of cutting-edge research, covering diverse aspects of cellular biochemistry and the physical principles that underlie biological systems. With an emphasis on interdisciplinary studies, the journal aims to facilitate knowledge exchange among researchers, professionals, and students from various scientific backgrounds. As reflected in its 2023 category rankings, it holds a respectable position in Q3 for Biochemistry and Cell Biology, and Q2 for both Biophysics and Medicine (miscellaneous), indicating its significant contribution to these fields. Although it operates under a subscription model, the journal's commitment to maintaining high publication standards ensures that only impactful studies are shared with its audience. With a range of articles spanning theoretical insights to practical applications, CELL BIOCHEMISTRY AND BIOPHYSICS is an essential resource for those aiming to stay at the forefront of biochemical and biophysical research.

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

Biomicrofluidics is a leading academic journal published by AIP Publishing, dedicated to disseminating cutting-edge research in the interface of microfluidics and biotechnology. Established in 2007 and continuing through 2024, this journal serves as a vital resource for researchers and professionals across various fields, including Biomedical Engineering, Colloid and Surface Chemistry, Condensed Matter Physics, and Nanoscience. With impactful insights and innovative methodologies, it maintains a commendable reputation, reflected in its impressive Scopus rankings, such as 24th in Fluid Flow and Transfer Processes and 10th in Colloid and Surface Chemistry. Although not an open-access journal, Biomicrofluidics ensures accessibility to its valuable content through various subscription options, facilitating knowledge sharing in scientific communities. This journal is essential for those at the forefront of microfluidic technologies and applications, offering a platform for exploring novel approaches and driving advancement in biomedical and engineering sciences.